Amedisys (AMED)
(Delayed Data from NSDQ)
$91.79 USD
+0.63 (0.69%)
Updated Apr 26, 2024 04:00 PM ET
2-Buy of 5 2
B Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMED 91.79 +0.63(0.69%)
Will AMED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMED
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Other News for AMED
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)
Amedisys: Q1 Earnings Snapshot
Amedisys Reports First Quarter 2024 Financial Results
AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024